MYRIAD GENETICS INC (MYGN) Stock News

USA - NASDAQ:MYGN - US62855J1043 - Common Stock

7.94 USD

-0.12 (-1.49%)

Last: 10/22/2025, 10:50:55 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

MYGN Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Myriad Genetics, Inc.

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

8 days ago - By: Myriad Genetics, Inc.

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

2 months ago - By: ACCESS Newswire

ANGLE Announces Collaboration with Myriad Genetics

14 days ago - By: D S Simon

Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV

20 days ago - By: Zacks Investment Research - Mentions: ILMN TMO QGEN

Illumina to Join Pharma Partners for CDx Development on KRAS Biomarker

a month ago - By: Sophia Genetics - Mentions: SOPH

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

a month ago - By: Myriad Genetics, Inc.

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

a month ago - By: Myriad Genetics, Inc. - Mentions: SOPH

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

a month ago - By: Zacks Investment Research - Mentions: PAHC MEDP NVST

MYGN Stock Might Gain on The Lancet Study Backing Precise MRD

2 months ago - By: Zacks Investment Research - Mentions: PAHC MEDP NVST

MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain?

2 months ago - By: Myriad Genetics, Inc.

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

2 months ago - By: Myriad Genetics, Inc.

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

2 months ago - By: Myriad Genetics, Inc.

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

2 months ago - By: Myriad Genetics, Inc.

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

2 months ago - By: Myriad Genetics, Inc.

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

2 months ago - By: Myriad Genetics, Inc.

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

2 months ago - By: Myriad Genetics, Inc.

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

2 months ago - By: Myriad Genetics, Inc.

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

2 months ago - By: Myriad Genetics, Inc.

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results

2 months ago - By: Myriad Genetics, Inc.

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results

2 months ago - By: Yahoo Finance

TD Cowen Maintained a Hold Rating on Myriad Genetics (MYGN)

3 months ago - By: Benzinga - Mentions: CYRX LNTH BIVI EOLS ...

12 Health Care Stocks Moving In Wednesday's Intraday Session